Expertise in
8
conditions

Dr. Donald Mcneil

Allergy and Immunology
Midwest Allergy Associates Inc.
8080 Ravines Edge Ct, 
Columbus, OH 
Expertise in
8
conditions
Midwest Allergy Associates Inc.
8080 Ravines Edge Ct, 
Columbus, OH 

Overview

Donald Mcneil is an Allergy and Immunologist in Columbus, Ohio. Dr. Mcneil is highly rated in 8 conditions, according to our data. His top areas of expertise are Primary Immunodeficiency (PID), Common Variable Immune Deficiency, Allergic Rhinitis, and Sinusitis.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Allergy and Immunology

Licenses

Allergy & Immunology in OH

Hospital Affiliations

Licking Memorial Hospital
Genesis Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Midwest Allergy Associates Inc.
8080 Ravines Edge Ct, Columbus, OH 43235

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: Completed
Publish Date: June 17, 2024
Intervention Type: Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: Completed
Publish Date: December 27, 2023
Intervention Type: Other, Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Subjects and Loading/Maintenance Dosing in Treatment-Naïve Subjects With Primary Immunodeficiency
A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Subjects and Loading/Maintenance Dosing in Treatment-Naïve Subjects With Primary Immunodeficiency
Enrollment Status: Completed
Publish Date: September 29, 2023
Intervention Type: Biological
Study Phase: Phase 4
A Phase 3, Multicenter, Open-label, Single-sequence, Cross-over, Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of IVIG-PEG Compared to Gamunex-C in Subjects With Primary Humoral Immunodeficiency
A Phase 3, Multicenter, Open-label, Single-sequence, Cross-over, Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of IVIG-PEG Compared to Gamunex-C in Subjects With Primary Humoral Immunodeficiency
Enrollment Status: Completed
Publish Date: June 05, 2023
Intervention Type: Biological
Study Phase: Phase 3
An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
Enrollment Status: Completed
Publish Date: December 09, 2022
Intervention Type: Biological
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Crossover Study to Evaluate the Efficacy and Safety of LY3454738 in Adults With Chronic Spontaneous Urticaria Inadequately Controlled With H1-Antihistamines
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Crossover Study to Evaluate the Efficacy and Safety of LY3454738 in Adults With Chronic Spontaneous Urticaria Inadequately Controlled With H1-Antihistamines
Enrollment Status: Terminated
Publish Date: March 11, 2022
Intervention Type: Drug
Study Drug: LY3454738
Study Phase: Phase 2
A Phase 3, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and PK of ProMetic BioTherapeutics IGIV (Human) 10% in Adults and Children With Primary Immunodeficiency Diseases
A Phase 3, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and PK of ProMetic BioTherapeutics IGIV (Human) 10% in Adults and Children With Primary Immunodeficiency Diseases
Enrollment Status: Completed
Publish Date: November 05, 2021
Intervention Type: Biological
Study Phase: Phase 3
A Double Blind, Randomized, Sham Controlled Trial to Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma
A Double Blind, Randomized, Sham Controlled Trial to Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma
Enrollment Status: Completed
Publish Date: November 03, 2020
Intervention Type: Device
Study Phase: Not Applicable
View 7 Less Clinical Trials

6 Total Publications

A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency.
A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency.
Journal: Journal of clinical immunology
Published: January 08, 2025
Similar Doctors
Expertise in
7
conditions
Dr. Elizabeth Erwin
Allergy and Immunology
Expertise in
7
conditions
Dr. Elizabeth Erwin
Allergy and Immunology

Nationwide Children's Hospital

700 Childrens Dr, 
Columbus, OH 
 (12.1 miles away)
614-722-4404
Languages Spoken:
English
See accepted insurances

Elizabeth Erwin is an Allergy and Immunologist in Columbus, Ohio. Dr. Erwin is highly rated in 7 conditions, according to our data. Her top areas of expertise are Eosinophilic Esophagitis, Esophagitis, Asthma, Grass Allergy, and Endoscopy.

Expertise in
12
conditions
Dr. Scott Bagenstose
Allergy and Immunology
Expertise in
12
conditions
Dr. Scott Bagenstose
Allergy and Immunology

Ohio ENT & Allergy Physicians

3545 Olentangy River Rd, Suite 200, 
Columbus, OH 
 (6.6 miles away)
614-827-0011
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Bagenstose is an Allergy and Immunologist in Columbus, Ohio. Dr. Bagenstose is highly rated in 12 conditions, according to our data. His top areas of expertise are Sinusitis, Allergic Rhinitis, Grass Allergy, and Allergic Conjunctivitis.

Expertise in
10
conditions
Dr. Roger Friedman
Allergy and Immunology
Expertise in
10
conditions
Dr. Roger Friedman
Allergy and Immunology

Ohio ENT & Allergy Physicians

3545 Olentangy River Rd, Suite 200, 
Columbus, OH 
 (6.6 miles away)
614-827-0011
Languages Spoken:
English
See accepted insurances

Roger Friedman is an Allergy and Immunologist in Columbus, Ohio. Dr. Friedman is highly rated in 10 conditions, according to our data. His top areas of expertise are Allergic Rhinitis, Sinusitis, Grass Allergy, and Common Variable Immune Deficiency.

Frequently Asked Questions about Dr. Donald Mcneil

How do I make an appointment with Dr. Donald Mcneil?

You can book an appointment with Dr. Donald Mcneil by calling their office at 614-846-5944. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Donald Mcneil a top-rated expert for Primary Immunodeficiency (PID)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Donald Mcneil is classified as an Distinguished expert for Primary Immunodeficiency (PID), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Donald Mcneil specialize in?

While Dr. Donald Mcneil is a Allergy and Immunology, they have specific expertise in Primary Immunodeficiency (PID), Common Variable Immune Deficiency, and Allergic Rhinitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Allergy and Immunology.

Does Dr. Donald Mcneil participate in research or clinical trials?

Yes. Dr. Donald Mcneil has published 6 articles and abstracts on conditions like Primary Immunodeficiency (PID). You can view a list of Dr. Donald Mcneil's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Donald Mcneil accept my insurance?

Dr. Donald Mcneil accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 614-846-5944 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mcneil's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile